ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Should Colchicine Become Standard Therapy for CAD?

Collaborative CME and Research Network

P. Ridker

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

Cardiology’s Biggest Controversy: The Lumen or the Wall - the Curiou…

Cedars Sinai

J. Forrester

IVUS: I’ve Been Doing This for 30-Years! Imaging Works Only IF

Controversies in Interventional Cardiovascular Therapies - CICT 2024

C. Di Mario

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

Co-Registration: Do We Really Need It? - 2025 Update

ARCH Advanced Revascularization Symposium

P. Thakker

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

ESC 2024 Insights: State-of-the-Art Lecture on Calcium Modification:…

ESC 2024 Insights

A. Kini

The History of Invasive Cardiac Procedures - Updated

Joel Gorfinkel

Combined ROTA and IVL for Treating a Severe Left Main Calcified Lesi…

ARCH Advanced Revascularization Symposium

L. Wei

Emotional Toll of Complications

The Christ Hospital Heart & Vascular Institute

W. Lombardi

Benefits of Slowing the Heart with Ivabradine

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians